Review
Current management of Barrett esophagus and esophageal adenocarcinoma
Tavankit Singh, MD, Vedha Sanghi, MD and Prashanthi N. Thota, MD, FACG
Cleveland Clinic Journal of Medicine November 2019, 86 (11) 724-732; DOI: https://doi.org/10.3949/ccjm.86a.18106
Tavankit Singh
Department of Gastroenterology and Hepatology, Cleveland Clinic
Vedha Sanghi
Department of Internal Medicine, Cleveland Clinic; Clinical Instructor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Prashanthi N. Thota
Medical Director, Esophageal Center, Digestive Disease and Surgery Institute, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
In this issue
Cleveland Clinic Journal of Medicine
Vol. 86, Issue 11
1 Nov 2019
Current management of Barrett esophagus and esophageal adenocarcinoma
Tavankit Singh, Vedha Sanghi, Prashanthi N. Thota
Cleveland Clinic Journal of Medicine Nov 2019, 86 (11) 724-732; DOI: 10.3949/ccjm.86a.18106
Jump to section
- Article
- ABSTRACT
- SCOPE OF THE PROBLEM
- GASTROESOPHAGEAL REFLUX DISEASE IS A RISK FACTOR FOR CANCER
- RISK FACTORS FOR BARRETT ESOPHAGUS
- SCREENING GUIDELINES AND DRAWBACKS
- SURVEILLANCE: WHAT’S INVOLVED, WHAT’S AVAILABLE
- MANAGEMENT OF NONDYSPLASTIC BARRETT ESOPHAGUS
- DOES CHEMOPREVENTION HAVE A ROLE?
- INDEFINITE DYSPLASIA
- ENDOSCOPIC ERADICATION: AN OVERVIEW
- LOW-GRADE DYSPLASIA: RECOMMENDED MANAGEMENT
- HIGH-GRADE DYSPLASIA: RECOMMENDED MANAGEMENT
- EARLY ESOPHAGEAL ADENOCARCINOMA: RECOMMENDED MANAGEMENT
- POSTABLATION MANAGEMENT
- References
- Figures & Data
- Info & Metrics






